IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer

Qian, Jingfeng; Ji, Fangxing; Xue, Yan; Cheng, Hongyan; Ma, Ruiqiong; Chang, Xiaohong; Shou, Chengchao; Cui, Heng

doi:10.21147/j.issn.1000-9604.2018.02.11

Cited by 11 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heavy and light chains of IgG have been detected in the cytoplasm of many human cancer cell lines [14]. The study found that IGHG1 was highly expressed in tumors such as ovarian cancer, and participates in pathological processes such as EMT, proliferation, apoptosis resistance, immune escape and metastasis of tumor cells [6,7]. Studies have also found that IGHG1 was significantly more expressed in pancreatic cancer tissues than in non-cancer tissues, IGHG1 downregulates the cytotoxic effects of NK cells by inhibiting the antigen-dependent cytotoxic function, leading to proliferation and immune escape of pancreatic cancer cells [15].…”

Section: Discussionmentioning

confidence: 99%

“…IGHG1 plays an important role in the occurrence and development of tumors. Its expression in ovarian cancer [6,7], pancreatic cancer [3], prostate cancer [8,9], papillary thyroid carcinoma [5] and other malignant epithelial tumors is significantly increased. It is involved in the pathological process of tumor cell EMT, proliferation, apoptosis resistance, immune escape and metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IGHG1 induces EMT in gastric cancer cells by regulating TGF-β/SMAD3 signaling pathway

Li¹,

Wang²,

Ye³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

IGHG1 induces EMT in gastric cancer cells by regulating TGF-β/SMAD3 signaling pathway

Li¹,

Wang²,

Ye³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

“…Previous studies have indicated that IGHG1 demonstrated promotive effects on tumor expansion in murine pancreatic cancer models [ 13 ]. Moreover, several studies on ovarian cancer, prostate cancer also indicated that IGHG1 promoted tumor migration and metastasis via modulating EMT [ 14 ] or MEK/ERK/c-Myc pathway [ 15 ]. Our study provided consistent results that IGHG1 significantly promoted proliferative and migrative capabilities of gastric cancer cells, which could be potential therapeutic target in future treatment development.…”

Section: Discussionmentioning

confidence: 99%

IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-Catenin pathway

Chen

Yang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Despite current advances in gastric cancer treatment, disease metastasis and chemo-resistance remain as major hurdles against better overall prognosis. Previous studies indicated that IGHG1 as well as -Catenin serve as important regulators of tumor cellular malignancy. Therefore, understanding detailed molecular mechanism and identifying druggable target will be of great potentials in future therapeutic development. Methods Surgical tissues and gastric cancer cell lines were retrieved to evaluate IGHG1 expression for patients with or without lymph node/distal organ metastasis. Functional assays including CCK8 assay, Edu assay, sphere formation assay and transwell assay, wound healing assay, etc. were subsequently performed to evaluate the impact of IGHG1/-catenin axis on tumor cell proliferation, migration and chemo-resistance. Results Gastric cancer tissues and tumor cell lines demonstrated significantly higher level of IGHG1. Functional study further demonstrated that IGHG1 promoted proliferative and migration as well as chemo-resistance of gastric cancer tumor cells. Further experiments indicated that IGHG1 activated AKT/GSK-3/-Catenin axis, which played crucial role in regulation of proliferative and chemo-resistance of gastric cancer cells. Conclusion This study provided novel evidences that IGHG1 acted as oncogene by promotion of gastric cancer cellular proliferation, migration and chemo-resistance. Our research further suggested that IGHG1/AKT/GSK-3β/β-Catenin axis acted as novel pathway which regulated gastric cancer cellular malignant behavior. Our research might inspire future therapy development to promote overall prognosis of gastric cancer patients.

show abstract

“…The FT tissue samples were harvested from patients who underwent a total hysterectomy and bilateral salpingo-oophorectomy for benign gynecological conditions. IHC staining was performed as previously described (15).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging

Zhang

Ling

Guo

et al. 2019

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

ObjectiveTo evaluate the imaging potential of a novel near-infrared (NIR) probe conjugated to COC183B2 monoclonal antibodies (MAb) in ovarian cancer (OC).MethodsThe expression of OC183B2 antigen in OC was determined by immunohistochemical (IHC) staining using tissue microarrays with the H-score system and immunofluorescence (IF) staining of tumor cell lines. Imaging probes with the NIR fluorescent dye cyanine 7 (Cy7) conjugated to COC183B2 Mab were chemically engineered. OC183B2-positive human OC cells (SKOV3-Luc) were injected subcutaneously into BALB/c nude mice. Bioluminescent imaging (BLI) was performed to detect tumor location and growth. COC183B2-Cy7 at 1.1, 3.3, 10, or 30 μg were used for in vivo fluorescence imaging, and phosphate-buffered saline (PBS), free Cy7 dye and mouse isotype immunoglobulin G (IgG)-Cy7 (delivered at the same doses as COC183B2-Cy7) were used as controls. ResultsThe expression of OC183B2 with a high H-score was more prevalent in OC tissue than fallopian tube (FT) tissue. Among 417 OC patients, the expression of OC183B2 was significantly correlated with the histological subtype, histological grade, residual tumor size, relapse state and survival status. IF staining demonstrated that COC183B2 specifically expressed in SKOV3 cells but not HeLa cells. In vivo NIR fluorescence imaging indicated that COC183B2-Cy7 was mainly distributed in the xenograft and liver with optimal tumor-to-background (T/B) ratios in the xenograft at 30 μg dose. The highest fluorescent signals in the tumor were observed at 96 h post-injection (hpi). Ex vivo fluorescence imaging revealed the fluorescent signals mainly from the tumor and liver. IHC analysis confirmed that xenografts were OC183B2 positive. ConclusionsCOC183B2 is a good candidate for NIR fluorescence imaging and imaging-guided surgery in OC.

show abstract

IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer

Abstract: IGHG1 promotes the motility of OC cells likely through executing the EMT program. Increased IGHG1 expression in OC specimens is associated with the lymph node metastasis.

Cited by 11 publications

References 22 publications

IGHG1 induces EMT in gastric cancer cells by regulating TGF-β/SMAD3 signaling pathway

IGHG1 induces EMT in gastric cancer cells by regulating TGF-β/SMAD3 signaling pathway

IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-Catenin pathway

Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging

Contact Info

Product

Resources

About